Autopsy report · NCT02393248
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
Cause of deathNo reason given
Life of this trial
- Ran for about 6 years 10 months before it stopped.
- 201 participants enrolled.
- Results were posted on the registry 1 year 1 month after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- Incyte Corporation
- Sponsor type
- Industry
- Conditions
- Lung Cancer; Solid Tumor; Gastric Cancer; Urothelial Cancer; Endometrial Cancer; Multiple Myeloma
- Interventions
- Pemigatinib; Gemcitabine; Pembrolizumab; Docetaxel; Trastuzumab; Retifanlimab
- Participants
- 201
- Sites
- 20
- Countries
- Denmark, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.